LIBTAYO® (Cemiplimab-rwlc)

The FDA on February 9, 2021 granted regular approval to LIBTAYO® for patients with Locally Advanced Basal Cell Carcinoma (laBCC) previously treated with a HedgeHog pathway Inhibitor (HHI) or for whom a HHI is not appropriate, and granted accelerated approval to LIBTAYO® for patients with metastatic BCC (mBCC) previously treated with a HHI or for whom a HHI is not appropriate. LIBTAYO® is a product of Regeneron Pharmaceuticals, Inc.